Navigation Links
Human Genome Sciences Announces Third Quarter 2007 Financial Results and Key Developments
Date:11/1/2007

become a breakthrough treatment for SLE. Phase 2 results through 2.5 years of LymphoStat-B treatment will be presented at the annual meeting of the American College of Rheumatology in Boston, November 6-11, 2007.

ABthrax(TM): Meeting Contract Milestones

HGS has met all milestones to date under its contract with the U.S. Government to supply 20,000 doses of ABthrax (raxibacumab) to the Strategic National Stockpile. The Company is working to conduct the additional clinical and laboratory studies required to support the filing of a Biologics License Application (BLA), and is on track to begin delivery to the stockpile in 2008. HGS expects to receive $165 million under the contract, with most of the revenue to come in 2008 and with the remainder to come when ABthrax is licensed by the FDA.

TRAIL Receptor Antibodies: Clinical and Preclinical Results

In October 2007, HGS presented new clinical and preclinical evidence of the anti-tumor activity and tolerability of the Company's TRAIL receptor antibodies for the treatment of cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco. The results of a Phase 1b trial demonstrated that HGS-ETR2 (lexatumumab) was safe and well tolerated in combination with four different standard chemotherapy regimens in patients with a wide range of cancer types. Objective responses were reported for two patients, and stable disease was observed in 22 patients.

The Company also presented preclinical data demonstrating that HGS-ETR1 (mapatumumab) and HGS-ETR2 in combination with chemotherapy synergistically enhanced anti-tumor activity in cholangiocarcinoma (cancer of the bile ducts). In a xenograft model of cholangiocarcinoma, the results demonstrated that HGS- ETR1 and either co-treatment or pre-treatment with cisplatin and gemcitabine were more effective than chemotherapy or HGS-ETR1 alone.

HGS is currently enrolling a randomized Phase 2 trial of H
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Primary Preadipocytes and Differentiated Adipocytes
2. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
3. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Human Universal cDNA Library Array I
6. Map and Link Human Genetic Disorders with SSLP Analysis
7. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
8. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
9. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
10. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
11. Sequence-Validated and Expression-Tested Human cDNA in a Dual Expression Vector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK, ... www.helixlife.com ), a private label distribution partnership serving the ... CEO, stated, "HelixLife gives GeneLink reach into new areas ... have not been available to us.  The HelixLife team ...
... September 24, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... scientists have spent the past 40 years describing the ... cell divides into two, they still haven,t agreed on ... contradictory theories, which now may be reconciled by a ... You. These findings could provide insights into the initiation ...
Cached Biology Technology:GeneLink Announces HelixLife Private Label Distribution Agreement 252-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 252-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 352-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 452-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 552-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 652-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 752-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 852-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 952-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 1052-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 1152-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 12Genetic switch underlies noisy cell division 2
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... - Researchers are developing new technologies that combine ... and tiny particles such as bacteria, viruses and ... drug manufacturing to food safety. The technologies ... "lab-on-a-chip" applications, or miniature instruments that perform measurements ...
... shown that, from the time that a woman starts trying ... on the time to pregnancy. Professor Roger Hart told ... and Embryology that the negative effect of gum disease on ... effect of obesity. Periodontal (gum) disease is a ...
... to the deserts of East Africa and has unique physical traits ... It has a lack of pain sensation in its skin ... underground with limited oxygen supply. For the first ... understand its longevity and resistance to diseases of ageing. Researchers ...
Cached Biology News:Laser, electric fields combined for new 'lab-on-chip' technologies 2Laser, electric fields combined for new 'lab-on-chip' technologies 3Gum disease can increase the time it takes to become pregnant 2Gum disease can increase the time it takes to become pregnant 3Scientists sequence DNA of cancer-resistant rodent 2
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
MarrowMAX Bone Marrow Medium...
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: